Astellas Pharma Inc. (TYO:4503)
Japan · Delayed Price · Currency is JPY 2,417.00
+27.50 (1.15%)
Sep 3, 2026, 3:30 PM JST
Astellas Pharma Ratios and Metrics
Market cap in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 4,333,714 | 4,512,563 | 2,589,390 | 2,946,773 | 3,381,409 | 3,519,738 | |
Market Cap Growth | 47.29% | 74.27% | -12.13% | -12.85% | -3.93% | 11.33% |
Enterprise Value | 4,680,649 | 4,985,287 | 3,324,889 | 3,565,926 | 3,003,971 | 3,170,189 |
Last Close Price | 2417.00 | 2519.00 | 1391.08 | 1508.43 | 1665.16 | 1636.75 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 11.90 | 15.48 | 51.03 | 172.88 | 34.26 | 28.37 |
Forward PE | 11.91 | 14.08 | 18.73 | 21.06 | 15.87 | 16.50 |
PS Ratio | 1.91 | 2.11 | 1.35 | 1.84 | 2.23 | 2.72 |
PB Ratio | 2.23 | 2.47 | 1.71 | 1.85 | 2.24 | 2.41 |
P/TBV Ratio | 9.23 | 11.54 | - | - | 5.48 | 6.59 |
P/FCF Ratio | 8.11 | 8.98 | 16.44 | 21.92 | 11.61 | 15.53 |
P/OCF Ratio | 7.32 | 8.06 | 13.31 | 17.09 | 10.32 | 13.67 |
PEG Ratio | - | 0.23 | 0.17 | 1.48 | 0.68 | 0.70 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 2.06 | 2.33 | 1.74 | 2.22 | 1.98 | 2.45 |
EV/EBITDA Ratio | 7.00 | 7.87 | 7.19 | 12.63 | 8.90 | 10.64 |
EV/EBIT Ratio | 9.92 | 11.35 | 12.62 | 28.62 | 12.97 | 14.53 |
EV/FCF Ratio | 8.76 | 9.92 | 21.11 | 26.53 | 10.31 | 13.98 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.30 | 0.37 | 0.62 | 0.63 | 0.14 | 0.15 |
Debt / EBITDA Ratio | 0.88 | 1.06 | 2.03 | 3.57 | 0.61 | 0.72 |
Debt / FCF Ratio | 1.10 | 1.34 | 5.95 | 7.50 | 0.70 | 0.94 |
Net Debt / Equity Ratio | 0.18 | 0.21 | 0.50 | 0.42 | -0.11 | -0.07 |
Net Debt / EBITDA Ratio | 0.52 | 0.62 | 1.62 | 2.38 | -0.51 | -0.34 |
Net Debt / FCF Ratio | 0.65 | 0.78 | 4.75 | 5.00 | -0.59 | -0.45 |
Asset Turnover | 0.65 | 0.62 | 0.55 | 0.53 | 0.63 | 0.56 |
Inventory Turnover | 1.36 | 1.30 | 1.28 | 1.38 | 1.76 | 1.60 |
Quick Ratio | 0.88 | 0.86 | 0.79 | 0.69 | 1.13 | 1.05 |
Current Ratio | 1.20 | 1.17 | 1.13 | 0.93 | 1.45 | 1.34 |
Return on Equity (ROE) | 21.30% | 17.44% | 3.26% | 1.10% | 6.65% | 8.72% |
Return on Assets (ROA) | 8.41% | 7.95% | 4.77% | 2.58% | 6.05% | 5.92% |
Return on Invested Capital (ROIC) | 16.18% | 15.17% | 11.63% | 4.72% | 12.83% | 12.80% |
Return on Capital Employed (ROCE) | 19.20% | 18.70% | 11.60% | 5.50% | 13.40% | 13.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 2, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 8.42% | 6.46% | 1.96% | 0.58% | 2.92% | 3.52% |
FCF Yield | 12.33% | 11.13% | 6.08% | 4.56% | 8.62% | 6.44% |
Dividend Yield | 3.31% | 3.10% | 5.32% | 4.64% | 3.60% | 3.06% |
Payout Ratio | 38.29% | 46.68% | 254.19% | 684.38% | 101.66% | 68.69% |
Buyback Yield / Dilution | -0.01% | 0.00% | 0.14% | 1.39% | 1.38% | 0.41% |
Total Shareholder Return | 3.29% | 3.10% | 5.46% | 6.03% | 4.98% | 3.46% |